How to Critically Appraise Prognostic Factor Studies Using the QUIPS Tool

Introduction

Prognostic Factor (PF) studies help clinicians predict what will happen to patients who already have a disease. They are central to guiding treatment intensity, planning follow-up, and managing expectations. However, the value of any PF study hinges on its methodological rigor.

To determine whether a PF study provides reliable, actionable information, we need to assess its internal validity (risk of bias) and external validity (applicability to the real-world clinical setting). This article walks through:

• What constitutes an ideal PF study design?
• How can PF studies be critically appraised using the QUIPS tool? (Quality in Prognosis Studies).

---

Part 1: Ideal Design for Prognostic Factor (PF) Studies

A. Object and Method Design: The DEPTh Perspective

According to the DEPTh model, PF studies fall within Prognosis research, with the object being the factor, the method being observation, and the analysis centering on prediction or causal influence.

B. Method Design Elements

1. Study Domain – “Who are we prognosticating?”

• Must include patients at risk of the outcome (e.g., hospital-acquired delirium among elderly inpatients).
• Patients must be free of the event at baseline (time zero).
• Example: A study on post-operative pulmonary complications in surgical patients should exclude those with pre-existing pulmonary disease at baseline.

2. Study Base – “Where do the patients come from?”

• Ideally a prospective cohort that:
  • Starts with all eligible patients at risk at time zero.
  • Measures PFs and confounders systematically.
  • Has complete follow-up for all patients.
• Avoid sampling distortions from referrals, case registers, or "found data" (e.g., retrospective chart reviews without standardization).

3. Study Determinants (PFs) and Covariates

• Must be measured validly, reliably, and consistently across all participants.
• Example: If studying frailty as a PF, use a validated frailty index, not undocumented clinical impressions.

4. Study Endpoints

• Should be clearly defined, reliably measured, and blind to PF status.
• Example: Time to hospital readmission should not depend on whether the PF was documented.

---

Part 2: The QUIPS Tool—Systematic Appraisal Framework

QUIPS evaluates six domains of bias in PF studies.

Domain 1: Study Participation

This addresses selection bias—are participants representative of the target population?

🔍 Key Judgments:

• High participation rate (≥80% desirable).
• Clear inclusion/exclusion criteria.
• Consecutive or random recruitment (not cherry-picked).

🧠 Example: A study examining depression severity and recovery in stroke patients should not include only patients from a rehabilitation clinic, as this excludes more severe cases.

Domain 2: Study Attrition

This evaluates loss to follow-up bias.

🔍 Key Judgments:

• Low attrition (<10%) is ideal.
• Documented reasons for loss.
• Demonstrated similarity between completers and dropouts.

🧠 Example: A study on weight loss after bariatric surgery loses 30% of participants with the highest BMI. This undermines the study’s conclusions about obesity's prognostic role.

Domain 3: Prognostic Factor Measurement

This tests PF measurement bias—was the factor assessed uniformly and accurately?

🔍 Key Judgments:

• Predefined PF definitions.
• Valid, objective, reproducible tools.
• Blinding to outcome status.

🧠 Example: Using self-reported physical activity versus actigraphy introduces recall bias and can skew the association with cardiovascular outcomes.

Domain 4: Outcome Measurement

Focuses on how reliably and equally outcomes were measured.

🔍 Key Judgments:

• Clear, valid definitions (e.g., stroke confirmed by imaging).
• Standard measurement protocols.
• Same method across PF levels.

🧠 Example: If patients with higher depression scores are more frequently assessed for suicide risk, this creates differential measurement bias.

Domain 5: Study Confounding

This domain assesses whether the PF-outcome link is biased by unmeasured or improperly handled confounders.

🔍 Key Judgments:

• All known confounders considered (age, sex, comorbidities).
• Measured with valid tools.
• Adjusted for using prespecified multivariable models.

🧠 Example: A study linking C-reactive protein (CRP) to cancer survival must adjust for cancer stage and treatment—otherwise, CRP might just be a marker of late-stage disease.

Domain 6: Statistical Analysis and Reporting

This addresses analytic integrity and transparency.

🔍 Key Judgments:

• Model building follows clear logic.
• All outcomes reported (no cherry-picking).
• Assumptions (e.g., proportional hazards in Cox models) are tested.

🧠 Example: A paper claims IL-6 predicts mortality but doesn’t mention that 4 other biomarkers were tested and not reported—raises concern about selective reporting bias.

---

Part 3: Synthesizing Risk of Bias Judgments

QUIPS recommends not summing up domain scores. Instead:

• Low risk = all key domains rated low.
• High risk = any one domain is high.
• Moderate risk = everything else.

Use sensitivity analysis to explore the effect of excluding high-risk studies from pooled estimates.

---

Key Takeaways

• Prognostic factor studies must start with patients at risk and follow them prospectively, measuring PFs and outcomes with equal rigor.
• The QUIPS tool dissects six critical areas of potential bias that map onto every phase of study conduct.
• High-quality PF studies underpin valid clinical predictions and support personalized care.
• When reading a PF study, always ask: Did the authors follow a clean, cohort-based logic from baseline to outcome?